Joined an alliance of life science companies dedicated to rare disease therapy development to support advocacy for policies that will improve processes for timely and cost-effective delivery of treatments
“Taysha is honored to be a founding member of the
As an education and advocacy-focused coalition of companies, the shared goal of the Coalition is to inform policymakers of the unique circumstances of the rare disease company business model, specifically focusing on the unique circumstances involved in developing and bringing to market therapies for small and differentiated patient population sizes. The Coalition will advocate for policy and regulatory frameworks that account for and recognize the distinct considerations of life science companies operating in the rare disease space and the impact it has on delivering innovative therapies to the patients they serve.
Founding members of the Coalition include:
- Acceleron Pharma
- Aeglea BioTherapeutics
- Agios Pharmaceuticals
- Alnylam Pharmaceuticals
- Harmony Biosciences
Orphazyme US, Inc.
- Sarepta Therapeutics
Taysha Gene Therapies
- Ultragenyx Pharmaceutical
In the coming month, the Coalition will engage with policy stakeholders on potentially impactful drug and healthcare policies and regulations currently under discussion, including prescription drug pricing, to highlight the consequences that blanket legislation can have on continued innovation for rare disease treatments.
SVP, Corporate Communications and Investor Relations